• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by Indivior PLC

    11/8/24 1:23:36 PM ET
    $INDV
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $INDV alert in real time by email
    6-K 1 a5943l.htm BLOCK LISTING INTERIM REVIEW a5943l
     
     
     
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    ________________________
     
    Washington, D.C. 20549
    _____________________
     
    FORM 6-K
    _____________________
     
    Report of Foreign Private Issuer
    Pursuant to Rule 13a-16 or 15d-16
    under the Securities Exchange Act of 1934
     
    For the month of November 2024
    Commission File Number: 001-37835
    ________________________________________
     
    Indivior PLC
    ________________________________________
     
    10710 Midlothian Turnpike, Suite 125
    North Chesterfield, Virginia 23235
     
    (Address of principal executive office)
     
    _______________________________
     
    Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F
     
    Form 20-F ☒ Form 40-F ☐
     
     
     
     
     
     
     
     
     
     
     
     
    EXHIBIT INDEX
     
    Exhibit No.
    Description of Exhibit
    99.1
    Announcement sent to the London Stock Exchange on November 08, 2024, titled “Block Listing Interim Review”.
     
     
     
     
     
     
     
    SIGNATURES
     
     
     
     
    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
     
     
     
     
     
    Indivior PLC
     
    Date: November 08, 2024
    /s/ Kathryn Hudson
     
    Name: Kathryn Hudson
     
    Title: Company Secretary
    Get the next $INDV alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $INDV

    DatePrice TargetRatingAnalyst
    8/6/2025$27.00Buy
    H.C. Wainwright
    7/22/2025$20.00Buy
    Jefferies
    1/28/2025$16.00Buy
    Rodman & Renshaw
    7/23/2024$22.00Overweight
    Piper Sandler
    4/3/2024$37.00Buy
    Craig Hallum
    7/13/2023$35.00Outperform
    Northland Capital
    More analyst ratings

    $INDV
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Indivior to Report Fourth Quarter and Full-Year 2025 Financial Results and Host Webcast on February 26ᵗʰ

    RICHMOND, Va., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc. (NASDAQ:INDV) today announced that it will report its fourth quarter and full-year 2025 financial results on Thursday, February 26, 2026, at 7:00 a.m. U.S. EST. Following the release of the financial results, Joe Ciaffoni, Chief Executive Officer, and other members of Indivior's leadership team will host a presentation via live webcast at 8:00 a.m. U.S. EST. Access to the Live Webcast Presentation: The webcast event and materials can be accessed on the "Investors" section of the company's website at www.indivior.com before the event begins. Live webcast link: https://edge.media-server.com/mmc/p/f78ufsat Par

    1/28/26 7:00:00 AM ET
    $INDV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Indivior Announces Completion of Redomiciliation to the United States

    RICHMOND, Va., Jan. 26, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc. (NASDAQ:INDV), today announced completion of its redomiciliation from the United Kingdom to the United States. As a result, Indivior Pharmaceuticals, Inc., a new Delaware corporation ("IPI"), has become the new parent company. Indivior PLC is renamed Indivior Ltd. and has become a wholly-owned subsidiary of IPI. The common stock of Indivior Pharmaceuticals, Inc., is listed on Nasdaq and will continue to trade under the symbol "INDV."The last day of trading Indivior PLC ordinary shares on Nasdaq was January 23, 2026. Shareholders of Indivior PLC received one new IPI common share for each Indivior PLC ordinary sh

    1/26/26 7:00:00 AM ET
    $INDV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Indivior Provides Full-Year 2026 Financial Guidance and Business Update

    Total Net Revenue Expected in the Range of $1,125 million to $1,195 millionTotal SUBLOCADE® Net Revenue Expected to be in the Range of $905 million to $945 millionNon-GAAP Operating Expenses Expected in the Range of $430 million to $450 millionAdjusted EBITDA Expected in the Range of $535 million to $575 million RICHMOND, Va., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Indivior PLC (NASDAQ:INDV) ("Indivior PLC" or the "Company") today announced its full-year 2026 financial guidance. "2025 was a transition year for Indivior in which we established the Indivior Action Agenda and completed Phase I – Generate Momentum – by growing U.S. SUBLOCADE net revenue, simplifying the organization and transform

    1/8/26 7:00:00 AM ET
    $INDV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $INDV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    H.C. Wainwright initiated coverage on Indivior with a new price target

    H.C. Wainwright initiated coverage of Indivior with a rating of Buy and set a new price target of $27.00

    8/6/25 8:01:45 AM ET
    $INDV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Jefferies resumed coverage on Indivior with a new price target

    Jefferies resumed coverage of Indivior with a rating of Buy and set a new price target of $20.00

    7/22/25 7:52:44 AM ET
    $INDV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rodman & Renshaw initiated coverage on Indivior with a new price target

    Rodman & Renshaw initiated coverage of Indivior with a rating of Buy and set a new price target of $16.00

    1/28/25 7:14:13 AM ET
    $INDV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $INDV
    SEC Filings

    View All

    SEC Form 15-12G filed by Indivior PLC

    15-12G - Indivior Pharmaceuticals, Inc. (0001625297) (Filer)

    1/26/26 4:10:43 PM ET
    $INDV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-8 filed by Indivior PLC

    S-8 - Indivior Pharmaceuticals, Inc. (0001625297) (Filer)

    1/26/26 4:10:42 PM ET
    $INDV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-8 POS filed by Indivior PLC

    S-8 POS - Indivior Pharmaceuticals, Inc. (0001625297) (Filer)

    1/26/26 4:04:19 PM ET
    $INDV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $INDV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Kingsley Stuart A was granted 3,722 shares, increasing direct ownership by 405% to 4,642 units (SEC Form 4)

    4 - Indivior Pharmaceuticals, Inc. (0001625297) (Issuer)

    1/28/26 4:11:47 PM ET
    $INDV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Wheadon David E. was granted 5,955 shares, increasing direct ownership by 41% to 20,350 units (SEC Form 4)

    4 - Indivior Pharmaceuticals, Inc. (0001625297) (Issuer)

    1/28/26 4:10:57 PM ET
    $INDV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Ryan Barbara was granted 3,722 shares, increasing direct ownership by 190% to 5,685 units (SEC Form 4)

    4 - Indivior Pharmaceuticals, Inc. (0001625297) (Issuer)

    1/28/26 4:10:09 PM ET
    $INDV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $INDV
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Ryan Barbara bought $27,429 worth of Ordinary Shares (775 units at $35.39), increasing direct ownership by 65% to 1,963 units (SEC Form 4)

    4 - INDIVIOR PLC (0001625297) (Issuer)

    1/7/26 1:51:48 PM ET
    $INDV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Humphreys Keith bought $27,429 worth of Ordinary Shares (775 units at $35.39), increasing direct ownership by 15% to 5,802 units (SEC Form 4)

    4 - INDIVIOR PLC (0001625297) (Issuer)

    1/7/26 1:50:38 PM ET
    $INDV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Ninivaggi Daniel A bought $27,429 worth of Ordinary Shares (775 units at $35.39), increasing direct ownership by 5% to 16,923 units (SEC Form 4)

    4 - INDIVIOR PLC (0001625297) (Issuer)

    1/7/26 1:49:33 PM ET
    $INDV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $INDV
    Leadership Updates

    Live Leadership Updates

    View All

    CRH, Carvana and Comfort Systems USA Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600

    NEW YORK, Dec. 5, 2025 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, December 22, to coincide with the quarterly rebalance. The changes ensure that each index is more representative of its market capitalization range. The companies being removed from the S&P SmallCap 600 are no longer representative of the small-cap market space.  Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Name Action Company Name Ticker GICS Sector Dec 22, 2025  S&P 500 Addition CRH CRH Mat

    12/5/25 5:49:00 PM ET
    $ASIX
    $BAH
    $BWA
    Major Chemicals
    Industrials
    Professional Services
    Consumer Discretionary

    Indivior Appoints Vanessa Procter as Executive Vice President of Corporate Affairs

    RICHMOND, Va., July 8, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq / LSE: INDV) today announced the appointment of Vanessa Procter as Executive Vice President of Corporate Affairs, effective July 7, 2025. Vanessa is a seasoned corporate affairs leader with extensive experience in the biopharmaceutical industry, and will be responsible for Corporate Communications, Government Affairs, Policy and Advocacy at Indivior. "We are excited to welcome Vanessa to the Indivior team," said Joe Ciaffoni, Chief Executive Officer. "Vanessa has an impressive track record of aligning teams to pr

    7/8/25 8:00:00 AM ET
    $INDV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Indivior Appoints Tony Kingsley to the Board of Directors

    RICHMOND, Va., June 24, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq / LSE: INDV) today announced the appointment of Tony Kingsley to the Board of Directors as an Independent Non-Executive Director, effective July 1, 2025. Mr. Kingsley was appointed pursuant to Indivior's relationship agreement with affiliates of Oaktree Capital Management, L.P., who supported his appointment. Tony Kingsley is an accomplished biopharmaceutical executive with a distinguished track record of building and leading organizations across multiple scientific disciplines, therapeutic areas, and stages of

    6/24/25 4:12:00 PM ET
    $INDV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $INDV
    Financials

    Live finance-specific insights

    View All

    Indivior to Report Fourth Quarter and Full-Year 2025 Financial Results and Host Webcast on February 26ᵗʰ

    RICHMOND, Va., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc. (NASDAQ:INDV) today announced that it will report its fourth quarter and full-year 2025 financial results on Thursday, February 26, 2026, at 7:00 a.m. U.S. EST. Following the release of the financial results, Joe Ciaffoni, Chief Executive Officer, and other members of Indivior's leadership team will host a presentation via live webcast at 8:00 a.m. U.S. EST. Access to the Live Webcast Presentation: The webcast event and materials can be accessed on the "Investors" section of the company's website at www.indivior.com before the event begins. Live webcast link: https://edge.media-server.com/mmc/p/f78ufsat Par

    1/28/26 7:00:00 AM ET
    $INDV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Indivior Reports Third Quarter 2025 Financial Results and Raises Full-Year 2025 Financial Guidance

    Q3'25 Total Net Revenue of $314m, up 2% YOY; Q3'25 SUBLOCADE® Net Revenue of $219m, up 15% YOYAnnounces the Optimization of Rest of World (ROW) Business Discontinued the Sales and Marketing Support of OPVEE®Expect Annual Operating Expense Savings of at Least $150m in 2026On Track to Enter Phase II of the Indivior Action Agenda — Accelerate — January 1, 2026Conference Call Scheduled for Today at 8:00 A.M. EasternRICHMOND, Va., Oct. 30, 2025 /PRNewswire/ -- Indivior PLC (NASDAQ:INDV) today reported its financial results for the third quarter ended September 30, 2025, and provided a business update.

    10/30/25 7:00:00 AM ET
    $INDV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Indivior to Report Third Quarter 2025 Financial Results and Host Webcast on October 30th

    RICHMOND, Va., Oct. 16, 2025 /PRNewswire/ -- Indivior PLC (NASDAQ:INDV) today announced that it will report its third quarter 2025 financial results on Thursday, October 30, 2025, at 7:00 a.m. U.S. ET. Following the release of the financial results, Joe Ciaffoni, Chief Executive Officer, and other members of Indivior's leadership team will host a presentation via live webcast at 8:00 a.m. U.S. ET. Access to the Live Webcast Presentation: The webcast event and materials can be accessed on the "Investors" section of the company's website at www.indivior.com before the event begi

    10/16/25 4:04:00 PM ET
    $INDV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $INDV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Indivior PLC

    SC 13G - INDIVIOR PLC (0001625297) (Subject)

    11/15/24 6:03:54 PM ET
    $INDV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Indivior PLC

    SC 13G/A - INDIVIOR PLC (0001625297) (Subject)

    11/14/24 5:00:25 PM ET
    $INDV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Indivior PLC

    SC 13D/A - INDIVIOR PLC (0001625297) (Subject)

    11/7/24 8:23:16 AM ET
    $INDV
    Biotechnology: Pharmaceutical Preparations
    Health Care